Revisiting cardiac injury during acute heart failure: further characterization and a possible target for therapy.

[1]  M. Nieminen,et al.  Long-term survival after hospitalization for acute heart failure--differences in prognosis of acutely decompensated chronic and new-onset acute heart failure. , 2013, International journal of cardiology.

[2]  P. Ponikowski,et al.  Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF , 2013, European heart journal.

[3]  Piotr Ponikowski,et al.  EURObservational Research Programme: regional differences and 1‐year follow‐up results of the Heart Failure Pilot Survey (ESC‐HF Pilot) , 2013, European journal of heart failure.

[4]  K. Swedberg,et al.  Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. , 2013, European heart journal.

[5]  P. Ponikowski,et al.  Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. , 2013, Journal of the American College of Cardiology.

[6]  Piotr Ponikowski,et al.  Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial , 2013, The Lancet.

[7]  G. Filippatos,et al.  Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. , 2012, European heart journal.

[8]  G. Felker,et al.  Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation , 2012, Clinical Research in Cardiology.

[9]  L. Tavazzi,et al.  Serial Measurement of Cardiac Troponin T Using a Highly Sensitive Assay in Patients With Chronic Heart Failure: Data From 2 Large Randomized Clinical Trials , 2012, Circulation.

[10]  V. Hasselblad,et al.  Troponin I in acute decompensated heart failure: insights from the ASCEND‐HF study , 2011, European journal of heart failure.

[11]  Carlo Lombardi,et al.  Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure: Analysis From the PROTECT Pilot Study , 2011, Circulation. Heart failure.

[12]  C. O'connor,et al.  Lessons learned from clinical trials in acute heart failure: phase 3 drug trials. , 2011, Heart failure clinics.

[13]  M. Gheorghiade,et al.  A review of phase II acute heart failure syndromes clinical trials. , 2011, Heart failure clinics.

[14]  S. Manzano-Fernández,et al.  Soluble ST2, high‐sensitivity troponin T‐ and N‐terminal pro‐B‐type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure , 2011, European journal of heart failure.

[15]  H. Katus,et al.  Troponin elevation in coronary vs. non-coronary disease. , 2011, European heart journal.

[16]  W. Peacock,et al.  Serial changes in high‐sensitive troponin I predict outcome in patients with decompensated heart failure , 2011, European journal of heart failure.

[17]  R. Porcher,et al.  Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF) , 2011, Intensive Care Medicine.

[18]  Christopher M O'Connor,et al.  Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. , 2010, Journal of the American College of Cardiology.

[19]  D. Atsma,et al.  Release kinetics of intact and degraded troponin I and T after irreversible cell damage. , 2008, Experimental and molecular pathology.

[20]  G. Fonarow,et al.  Cardiac troponin and outcome in acute heart failure. , 2008, The New England journal of medicine.

[21]  Peter C Austin,et al.  Relation between cardiac troponin I and mortality in acute decompensated heart failure. , 2007, American heart journal.

[22]  V. Hasselblad,et al.  The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). , 2005, The American journal of cardiology.

[23]  Gerasimos Filippatos,et al.  Pathophysiologic targets in the early phase of acute heart failure syndromes. , 2005, The American journal of cardiology.

[24]  Eduardo R Perna,et al.  Minor myocardial damage detected by troponin T is a powerful predictor of long-term prognosis in patients with acute decompensated heart failure. , 2005, International journal of cardiology.

[25]  A. Barbagelata,et al.  Ongoing Myocardial Injury in Stable Severe Heart Failure: Value of Cardiac Troponin T Monitoring for High-Risk Patient Identification , 2004, Circulation.

[26]  T Kita,et al.  Biochemical markers of myocyte injury in heart failure , 2004, Heart.

[27]  J. Canty,et al.  Preload Induces Troponin I Degradation Independently of Myocardial Ischemia , 2001, Circulation.

[28]  P A Poole-Wilson,et al.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.

[29]  G. Heusch,et al.  Development of Short‐term Myocardial Hibernation Its Limitation by the Severity of Ischemia and Inotropic Stimulation , 1993, Circulation.